


Study Group – Renal Cell Cancer

The introduction of tyrosine-kinase-inhibitors (TKIs) as well as the use of immune-modulating targeted agents/check-point inhibitors (CPIs) led to a dramatic change in the treatment landscape of metastatic RCC. Despite the huge clinical benefit still the majority of patients will not experience a long-term benefit. Aim of this project is to provide the inventory platform of clinical data and biomaterials for a thorough and comprehensive analysis to increase the knowledge of predictive and prognostic factors as well as mechanisms of resistance or immune exhaustion.

Speakers: Prof. Dr. Peter J. Goebell, Erlangen
Prof. Dr. Arndt Hartmann, Erlangen

Concept & Achievements



Future Milestones

- » Redefine and expand initial cohort (adjuvant/non-clear cell RCC)
- » Explore CARAT, SUNNIFORCAST and RWD as validation cohorts
- » Implement newly identified relevant molecular alterations (especially for non-clear cell RCC)
- » Explore inter-lab exchange (personel/post-docs)
- » Expand clinical and biomaterial inventory across BZKF sites
- » Application trials implementing sequencing, liquid samples, single cell suspensions and tumor organoids

Authors: Casuscelli J (LMU), Goebell PJ (UR Erlangen), Hartmann A (UK Erlangen), Jordan F (UK Augsburg), Kalogirou Ch (UK Würzburg), Kübler H (UK Würzburg), Lunger L (TUM), Mayr R (UK Regensburg), Pichler M (UK Augsburg), Rodler S (LMU), Siska P (UK Regensburg), Steinestel J (UK Augsburg), Tauber R (TUM)